Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.45 |
| ▸ | GRK3 | P35626 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608023 | 0.78 | EPHX2 (0.45) | TSHRCYP2D6NPC1ALDH1A1CYP2C19 | |
| SCHEMBL28028435 | 0.78 | EPHX2 (0.45) | TSHRCYP2D6NPC1ALDH1A1CYP2C19 | |
| SCHEMBL17303495 | 0.77 | RXRA (0.37) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL13900538 | 0.75 | DRD4 (0.62) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL17300748 | 0.75 | HTR1A (0.37) | HTR1AEPHX2 | |
| SCHEMBL19633625 | 0.75 | NOS3 (0.38) | HTR1AALDH1A1 | |
| SCHEMBL6965778 | 0.75 | MAOA (0.49) | HTR1AADRA1AADRA1DADRA1BCYP2D6 | |
| SCHEMBL4190714 | 0.74 | KDM4E (0.50) | TSHRCYP2D6NPC1ALDH1A1CYP2C19 | |
| SCHEMBL2569101 | 0.74 | HTR1B (0.55) | HTR1AADRA1AADRA1DADRA1BALDH1A1 | |
| SCHEMBL31143619 | 0.73 | L3MBTL1 (0.46) | TSHRCYP2D6NPC1ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | HTR1A 4385/4885ADRA1A 3237/4885ADRA1D 3462/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | HTR1A 4385/4885ADRA1A 3237/4885ADRA1D 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.